NCT06868290 - Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

June 7, 2029

Study Completion Date

May 24, 2030

Conditions

ANCA Associated Vasculitis (AAV)

Interventions

BIOLOGICAL

Rapcabtagene autoleucel

Single infusion of rapcabtagene autoleucel

OTHER

Active Comparator

Active comparator option as per protocol

DRUG

Glucocorticoids

Concomitant glucocorticoids as per protocol

Trial Locations (17)

3010

RECRUITING

Novartis Investigative Site, Bern

4031

RECRUITING

Novartis Investigative Site, Basel

11211

RECRUITING

Novartis Investigative Site, Riyadh

60611

RECRUITING

Northwestern Memorial Hospital, Evanston

84143

RECRUITING

LDS Hospital, Salt Lake City

97239

RECRUITING

Oregon Health Sciences University, Portland

119074

RECRUITING

Novartis Investigative Site, Singapore

2608677

RECRUITING

Novartis Investigative Site, Chiba

3109601

RECRUITING

Novartis Investigative Site, Haifa

5265601

RECRUITING

Novartis Investigative Site, Ramat Gan

060 8648

RECRUITING

Novartis Investigative Site, Sapporo

650-0047

RECRUITING

Novartis Investigative Site, Kobe

920 8641

RECRUITING

Novartis Investigative Site, Kanazawa

980 8574

RECRUITING

Novartis Investigative Site, Sendai

565 0871

RECRUITING

Novartis Investigative Site, Suita

606 8507

RECRUITING

Novartis Investigative Site, Kyoto

S308433

RECRUITING

Novartis Investigative Site, Singapore